App is designed to be used by clinicians at the point of care. The algorithm used is based on the American Academy of Pediatrics 2004 recommendations for “Management of Hyperbilirubinemia in Infants Greater than 35 Weeks of Age”. The application calculates the threshold for starting phototherapy based on the patient’s age, bilirubin level, and neurotoxicity risk. Bilirubin value is displayed on the phototherapy nomogram as well as on the Bhutani nomogram that assesses risk level for further hyperbilirubinemia (>95th percentile for age).
BOTTOM LINE: Hyperbilirubinemia treatment decisions cannot be based on BiliCalc alone. However, BiliCalc can serve to support clinical judgment in the treatment of straightforward jaundice in the full term well newborn infant. It has a clean, easy to use user-interface and the recommendations are based on sound, evidence-based content. Future versions of this app could improve on this version by enabling entry of bilirubin levels at multiple points in time; thus, permitting the app to move beyond a single point bilirubin measure to assess hyperbilirubinemia risk. Also, enabling personalization to individual patients would allow quick reference when reassessing multiple newborns. Providing more detailed decision guidance would also be a welcomed improvement.